You are here

Matthew Stoll, PhD

Matthew Stoll, PhD
 
Associate Professor
Department of Pediatrics
Division of Pediatric Rheumatology
1601 4th Ave South
Birmingham, AL 35233
Phone: (205) 638-9438
E-mail: mstoll@peds.uab.edu
Full CV

Dr. Stoll is a pediatric rheumatologist who earned his MD and PhD at Upstate Medical University (Syracuse, NY) in 2001, followed by completion of residency in pediatrics at the Long Island Jewish Medical Center in 2004 and fellowship in pediatric rheumatology at the Childrens Hospital Boston in 2007. At the completion of his fellowship, he took a staff position at the University of Texas at Southwestern Medical Center (Dallas, TX), where he earned an MSCS degree. In 2011, he moved to the University of Alabama at Birmingham and was promoted to the level of Associate Professor in October of 2014. During his fellowship, Dr. Stoll developed an interest in the clinical epidemiology of spondyloarthritis, publishing on age-based subgroups of juvenile psoriatic arthritis as well as risk factors for sacroiliitis in patients with pediatric spondyloarthritis. He subsequently turned his attention to the links between spondyloarthritis and inflammatory bowel disease and reported on use of fecal calprotectin as well as intestinal MRI to identify sub-clinical intestinal inflammation in children with spondyloarthritis. His current work focuses on the role of the intestinal microbiota in the pathogenesis of spondyloarthritis, as well as on therapeutic dietary manipulations. He is currently studying the ability of dietary manipulation to impact the microbiota and disease severity in a mouse model of arthritis.

Education:

  • 1994 - B.A. (Molec. Biology & Biochem.) Wesleyan University (Middletown, CT)
  • 2001 - M.D., Ph.D. (Immunology) SUNY Upstate Medical University (Syracuse, NY)
  • 2011 - M.S.C.S. UT Southwestern Medical Center (Dallas, TX)

Publications:

  1. Stoll M, Gavalchin J. Systemic lupus erythematosus—messages from experimental models. Rheumatology 2000; 39:18-27.
  2. Price K, Knupp CJ, Tatum AH, Jiang F, Stoll ML, Gavalchin J. Molecular identification of pathogenic IdLNF1 autoantibody idiotypes derived from the (NZB x SWR)F1 model for systemic lupus erythematosus. Journal of Autoimmunity 2002; 19: 87-101.
  3. Stoll ML, Listman JA. Nephrolithiasis in a neonate with transient renal wasting of calcium and magnesium. Pediatric Nephrology 2002; 17: 386-389.
  4. Brown K, Ratner M, Stoll M. Pheochromocytoma unmasked by imipramine in an 8-year old girl. Pediatric Emergency Care 2003; 19: 174-177.
  5. Stoll ML, Gauthier BG, Vergara M, Ramek J, Frank R, Trachtman H. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF. Pediatric Nephrology 2004; 19: 120-121.
  6. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children presenting to a children’s hospital emergency department or urgent care center in the era of the pneumococcal conjugate vaccine. Archives of Pediatric and Adolescent Medicine 2004; 158: 671-675.
  7. Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis and Rheumatism 2006; 54: 3564-3572.
  8. Stoll ML, Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: a review of the literature. Clinical and Developmental Immunology 2006; 13): 377-380.
  9. Stoll ML, Price KD, Silvin CJ, Jiang F, Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR x NZB)F1 murine model. Journal of Autoimmunity 2007; 29: 30-37.
  10. Stoll ML, Gotte AC. Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from adult and pediatric experiences. Biologics: Targets and Therapies 2008; 2: 229-252.
  11. Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for Rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Care and Research 2008; 59: 51-58.
  12. Stoll ML, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA. TNFα inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma. Journal of Clinical Rheumatology 2009; 15: 198-200.
  13. Simard JF, Stoll ML, Shadick NA, Karlson EW, Solomon DH. Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity. Journal of Clinical Epidemiology 2010; 63: 1358-1362.
  14. Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. Journal of Rheumatology 2010; 37: 2402-2408.
  15. Stoll ML, Nigrovic PA, Gotte AC, Punaro M. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2011; 29: 582-588.
  16. Stoll ML. Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clinical and Experimental Rheumatology 2011; 29: 322-330.
  17. Stoll ML, Li Q, Zhou J, Punaro M, Olsen N. Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course. Clinical and Experimental Rheumatology 2011; 29: 736-742.
  18. Stoll ML, Patel AS, Punaro M. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. Journal of Rheumatology 2011; 38: 2274-2275.
  19. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Current Opinion in Rheumatology 2011; 23: 437-443.
  20. Stoll ML, Patel AS, Punaro M, Dempsey-Robertson M. MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. Pediatric Rheumatology 2012; 10: 6.
  21. Feng F, Silvin C, Fiore N, Stoll M, Shanley P, Silverstone AE, and Gavalchin J. 17β-Estradiol (E-2) administration to male (NZB x SWR)F1 mice results in increased IdLNF1-reactive memory T-lymphocytes and accelerated glomerulonephritis. Lupus, 2012; 21: 288-301.
  22. Stoll ML, Patel AS, Christadoss ML, Punaro M, Olsen NJ. IgA transglutaminase levels in children with juvenile idiopathic arthritis. Annals of Paediatric Rheumatology 2012; 1: 31-35.
  23. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider, R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe R, Weiss J, Weiss P, Ilowite N, Wallace C. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care and Research 2012; 64: 1001-1010.
  24. Stoll ML, Good J, Sharpe T, Beukelman T, Young D, Waite PW, Cron RQ. Intraarticular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. Journal of Oral and Maxillofacial Surgery 2012; 70: 1802-1807.
  25. Stoll ML, Sharpe T, Beukelman T, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. Journal of Rheumatology 2012; 39: 1880-1887.
  26. Nyland JF, Stoll ML, Jiang F, Feng F, Gavalchin J. Mechanisms involved in the p62-73 idiopeptide-modulated delay of lupus nephritis in SNF(1) mice. Lupus 2012; 21:1552-1564.
  27. Stoll ML, Morlandt A, Teerawattanapong S, Young D, Waite PD, Cron RQ. Safety and efficacy of intra-articular infliximab therapy for treatment resistant temporomandibular joint arthritis in children: a retrospective study. Rheumatology 2013; 52: 554-559.
  28. Henderson LA, Loring SL, Gill RR, Liao KP, Ishizawar R, Kim S, Perlmutter-Goldenson R, Rothman D, Son MB, Stoll ML, Zemel LS, Sandborg C, Dellaripa PF, Nigrovic PA. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. Journal of Rheumatology 2013; 40: 273-281.
  29. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. Journal of Rheumatology 2013; 40: 1749-1755.
  30. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in the biologic age. Rheumatic Disease Clinics of North America 2013; 39: 751-766.
  31. Vaid YN, Dunnavant DF, Royal SA, Beukelman T, Stoll ML, Cron RQ. Imaging of the temporomandibular joint in juvenile idiopathic arthritis. Arthritis Care and Research 2014; 66: 47-54.
  32. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatric Rheumatology 2014; 12:13.
  33. Kimura Y, Morgan Dewitt E, Beukelman T, Stoll ML, Nigrovic PA, Onel K, Prahalad S, et al. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis. Arthritis Care and Research 2014; 66: 1430-1431.
  34. Stoll ML, Kumar R, Morrow CD, Lefkowitz EJ, Cui X, Genin A, Cron RQ, Elson CO. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Research and Therapy 2014; 16:486.
  35. Tambralli A, Beukelman T, Cron RQ, and Stoll ML. Safety and efficacy of rituximab in childhood-onset lupus and other rheumatic diseases. Journal of Rheumatology 2015;42:541-546.
  36. Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, Lopez Benitez J, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE. Novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project. Arthritis Care and Research 2015; 67: 529-537.
  37. Stoll ML, Cron RQ, and Saurenmann RT. Systemic and intra-articular anti-inflammatory therapy of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. Seminars in Orthodontics, 2015; 21:125-133.
  38. Stoll ML. Gut microbes, immunity, and spondyloarthritis. Clinical Immunology, 2015;159:134-142.
  39. Stoll ML, Vaid Y, Gurash S, Beukelman T, Waite PD, Cron RQ. Magnetic resonance imaging findings following intra-articular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis. Journal of Rheumatology 2015; 42:2155 - 2159.
  40. Stoll ML and Cron RQ. Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: The Last Frontier. International Journal of Clinical Rheumatology 2015; 10:273-286.
  41. Arvonen M, Berntson L, Pokka T, Karttunen TJ, Vähäsalo P, Stoll ML. Gut Microbiota-Host Interactions and Juvenile Idiopathic Arthritis. Pediatric Rheumatology 2016; 14:44.
  42. Mannion M, McAllister L, Cron RQ, Stoll ML. Ustekinumab as a therapeutic option for children with refractory enthesitis-related arthritis. Journal Clinical Rheumatology 2016; 22:282.
  43. Stoll ML, Cron RQ. The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target? Current Opinion in Rheumatology 2016; 28:537.